Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
– Prioritizing development of wholly owned clinical assets, WTX-124 and WTX-330; key updates from both INDUKINETM programs anticipated in 2024 –
Related news for (HOWL)
- Don’t Miss Out: MoBot’s Latest Stock Updates 09/22/25 05:00 PM
- MoBot alert highlights: NASDAQ: LIMN, NASDAQ: SLE, NYSE: BFLY, NASDAQ: SLNH, NASDAQ: HOWL (09/22/25 04:00 PM)
- MoBot alert highlights: NASDAQ: KITT, NASDAQ: VUZI, NASDAQ: HOWL, NASDAQ: BETRW, NASDAQ: KOD (09/22/25 01:00 PM)
- Werewolf Therapeutics to Participate in the BIO International Convention
- Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update